Voriconazole

Vfend

Antifungal • Triazole antifungal

Premium

NTIQT RiskHepatotoxic

Half-life

6 hours (dose-dependent)

Protein Binding

58%

Metabolized By

CYP2C19, CYP2C9, CYP3A4

External

Drugs.com

Boxed warning

Hepatotoxicity
Visual disturbances
Embryo-fetal toxicity

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits fungal CYP450-dependent 14-alpha-demethylase

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Leukemia, Myeloid, Acute
·Leukemia, Lymphocytic, Acute
·Multiple Myeloma
·Myelodysplastic Syndromes
·Healthy Volunteers

Monitoring

Therapeutic range: 1–5.5 mg/L; Ctrough 1-5.5 mg/L

Interactions

No curated interaction pairs are recorded for Voriconazole. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Visual disturbances
Hepatotoxicity
Rash
QT prolongation
Photosensitivity

Food, alcohol & herbal

Food

Take 1 hour before or after meals

Alcohol · moderate

Additive hepatotoxicity

Herbal

St. John's Wort (major) — Dramatically reduces voriconazole levels — CONTRAINDICATED

Pharmacokinetics

Published parameters · PMID:22025530

Half-life: 6 hours (dose-dependent)
Protein binding: 58%
Metabolised by: CYP2C19, CYP2C9, CYP3A4
Inhibits: CYP2C19, CYP2C9, CYP3A4
Clearance: 5 L/h; adult patients with invasive fungal infections
Volume of distribution: 200 L
Bioavailability: 96%
Renally eliminated: 2%
Model: Michaelis-Menten (non-linear)

Pregnancy & lactation

Not recorded for Voriconazole. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Voriconazole

Vfend

Antifungal • Triazole antifungal

Premium

NTIQT RiskHepatotoxic

Half-life

6 hours (dose-dependent)

Protein Binding

58%

Metabolized By

CYP2C19, CYP2C9, CYP3A4

External

Drugs.com

Boxed warning

Hepatotoxicity
Visual disturbances
Embryo-fetal toxicity

Clinical alerts

Boxed warning

3 boxed warnings

Narrow therapeutic index

Small dose changes can cause toxicity or loss of effect

QT prolongation

Avoid combining with other QT-prolonging agents; check electrolytes

Hepatotoxic

Monitor liver function

Mechanism of action

Inhibits fungal CYP450-dependent 14-alpha-demethylase

Recorded indications

From the drug index — may include conditions studied rather than approved indications

·Leukemia, Myeloid, Acute
·Leukemia, Lymphocytic, Acute
·Multiple Myeloma
·Myelodysplastic Syndromes
·Healthy Volunteers

Monitoring

Therapeutic range: 1–5.5 mg/L; Ctrough 1-5.5 mg/L

Interactions

No curated interaction pairs are recorded for Voriconazole. This is not a statement that none exist — check a full interaction reference before combining.

Common adverse effects

Visual disturbances
Hepatotoxicity
Rash
QT prolongation
Photosensitivity

Food, alcohol & herbal

Food

Take 1 hour before or after meals

Alcohol · moderate

Additive hepatotoxicity

Herbal

St. John's Wort (major) — Dramatically reduces voriconazole levels — CONTRAINDICATED

Pharmacokinetics

Published parameters · PMID:22025530

Half-life: 6 hours (dose-dependent)
Protein binding: 58%
Metabolised by: CYP2C19, CYP2C9, CYP3A4
Inhibits: CYP2C19, CYP2C9, CYP3A4
Clearance: 5 L/h; adult patients with invasive fungal infections
Volume of distribution: 200 L
Bioavailability: 96%
Renally eliminated: 2%
Model: Michaelis-Menten (non-linear)

Pregnancy & lactation

Not recorded for Voriconazole. Absence here means this database does not hold a category — not that the drug is safe in pregnancy or breastfeeding.

Sources

Assembled from: drug index, curated drug database, published PK literature.

Not a substitute for clinical judgement

Voriconazole Drug Profile | PharmaGraphX